Le Lézard
Classified in: Health
Subjects: PDT, TDS, MAT

iCAN: Israel-Cannabis a Global Leader in Cannabis Investments and Conferences Announces Formation of Psychedeli-Tech, a Conference and Discovery Platform for Psychedelic Science, Innovation, Investment, Regulation and Medicine


TORONTO, Nov. 18, 2019 /PRNewswire/ -- iCAN: Israel-Cannabis, the world's premier cannabis technology incubator and owner of the CannaTech event platform, announced the formation of Psychedeli-Tech (PsyTech), a new and exciting conference and discovery platform for psychedelic medicine. While cannabis innovation aligns with the regulatory expansion over the past 5 years, the psychedelic therapy market is only just beginning with U.S., cities such as Portland, Chicago, Berkeley and Dallas in various stages of legalisation and decriminalisation. This rapidly developing new industry is paving the way for ground-breaking treatments utilizing psychedelic medicines.

Like cannabis, psychedelics have been used in traditional medical practice for thousands of years and only in the last century has the regulation prevented further study and benefit of these medicines.

Growing evidence points to the potential of psychedelics in the treatment of mental health disease and symptoms, including depression and anxiety disorders, obsessive-compulsive disorder, and alcohol and tobacco dependence. Clinical trials on psychedelic therapies are now underway in some of North America's most prestigious universities including Yale, John Hopkins, New York University and University of California, Los Angles.

In addition to the conference, PsyTech will help companies access capital, IP and incubation services allowing it to become the premier incubator and investor in psychedelic discovery. Psychedelics have the chance to impact mental health with the global market for mental health medications worth $88.3 billion in 2015, according to BCC Research.

Founder & CEO of iCAN: Israel Cannabis and CannaTech, Saul Kaye said: "For the past 5 years we have been building iCAN & CannaTech to drive the global cannabis ecosystem and to educate and innovate the best cannabis therapeutics and products around the world. I believe that the future of medical care will expand beyond traditional pharmaceuticals, and cannabis, as well as psychedelic treatments, will give patients access to a wider range of treatments. Similar to the cannabis industry, psychedelics and medicinal mushrooms will require an ecosystem to effectively drive education, regulation, safety, investment, research and development."

Ronnie Eshel, Director of Life Sciences at iCAN noted that: "Millions of people around the world suffer from depression, PTSD, anxiety, addiction and other debilitating chronic conditions, and there is growing evidence that psychedelics may have the potential to provide a better treatment path for many of these patients. I am thrilled that iCAN: Israel-Cannabis has formed PsyTech to build an ecosystem that will drive scientific discovery forward."

The first PsyTech conference will take place in Tel Aviv, Israel on March 29-30, 2020.

For more details and to apply for sponsorship or speaking opportunities or if you are interested in investing in this industry, please contact deborah@psytech.biz

About PsyTech:

PsyTech, a division of iCAN: Israel-Cannabis is a global events platform and innovation scout for psychedelic medicine. For the PsyTech website click here.

About iCAN: Israel-Cannabis

iCAN: Israel-Cannabis is building the Global Cannabis Ecosystem. iCAN is committed to accelerate Israel's Canna-Technology industry, capitalizing on Israeli innovation and a leading cannabis regulatory environment to bring premier products to market. iCAN is powered by CannaTech, the premier international cannabis summit held annually in Tel Aviv, and around the world, including London, Sydney, Hong Kong and Panama to date and upcoming in Cape Town in November 2019. Click here for more information about iCAN.

About CannaTech

CannaTech is the only Medical Cannabis event of its kind with a global focus that offers senior industry leaders, medical and scientific experts, and new ventures the platform to come together, drive innovation, form partnerships and promote knowledge exchange.  For more information about CannaTech click here.

Media Contact: 

Laura Kam
laura@kamgs.com
+972-54-806-8613

SOURCE iCAN


These press releases may also interest you

at 18:20
bluebird bio, Inc. and Bristol-Myers Squibb announced updated safety and efficacy results from the ongoing Phase 1 study (CRB-402) of bb21217, an investigational BCMA-targeted chimeric antigen receptor (CAR) T cell therapy being studied in patients...

at 18:20
Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today presented topline data from the ASCERTAIN phase 3 trial of the orally administered fixed dose combination of cedazuridine and...

at 17:50
Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, presented today at the American Society of Hematology annual meeting data from a Phase 1 study of its bivalent T cell...

at 17:40
Welltower Inc. announces that on December 24, 2019, it is redeeming all of the outstanding 3.35% Senior Notes due November 25, 2020 (the "Notes") issued by HCN Canadian Holdings-1 LP, its wholly-owned subsidiary, in accordance with the terms of the...

at 17:20
Quest Diagnostics Incorporated , the world's leading provider of diagnostic information services, announced today the pricing of a public offering of $800 million aggregate principal amount of its 2.950% senior notes due 2030 under the Quest...

at 17:20
Bariatric Surgery Devices (General Surgery) - Global Market Analysis and Forecast Model Read the full report: https://www.reportlinker.com/p05830908/?utm_source=PRN Summary Bariatric Surgery Devices (General Surgery) - Global Market Analysis and...



News published on 18 november 2019 at 09:00 and distributed by: